# MCI Capital - the worst is already priced in?

MCI Capital is doing very well in a difficult market environment. Good investments more than cover losses from less profitable projects. Low valuations at MCI.TV provide an opportunity to rebuild value after the market rebounds, and we feel investments such as eSky and netrisk will drive performance in the coming quarters and years. In addition, the company has cash reserves that it can use for further acquisitions. After updating our forecasts, we are adjusting our valuation of MCI Capital shares from PLN 29.6 to PLN 36.1.

# Results for 2022 - MCI.EV profits more than covered MCI.TV losses

In total, throughout 2022, unrealized gains on the valuation of MCI.EV FIZ amounted to PLN 280m, and unrealized losses on the valuation of MCI.TV FIZ amounted to PLN 120m. Total investment income in 2022 amounted to PLN 141m, net income to PLN 143m, and book value per share to PLN 36.5. The results of MCI.EV FIZ were affected by the revaluation of investments in eSky (PLN +276m) and Netrisk (PLN +49m), offset by a negative result on the revaluation of IAI (PLN -51m) and Pigu (PLN -34m). The results of the entire MCI.TV FIZ were mainly affected by the revaluation of investments in Morele Group (PLN -155m), Gett (PLN -73m) and Travelata.ru (PLN -31m).

# Assets at end of 1Q23 similar q/q

According to information published by the company, the gross assets of the MCI.PrivateVentures FIZ fund, in which most of the MCI Group's assets are accumulated, rose to PLN 2.54 billion at the end of March this year, compared to PLN 2.53 billion at the end of 2022. According to our estimates, this translates into several million zlotys of net profit in 1Q23. The current stock market is more favorable to acquisitions than exits and the MCI Group, with liquidity of PLN 732m, is very well positioned for further investments. We feel that the Group's performance in 2023 will be determined mainly by the results of MCI.EV FIZ, of which we expect value growth mainly in the case of eSky, generating high growth rates of earnings improvement.

### Risks for our forecasts and valuation

Main risk factors for our valuation are limited portfolio liquidity, high concentration of portfolio investments and the adopted valuation method for certain portfolio companies.

# Our valuation is equally based on NAV (PLN38/share) and peers valuation to the other PE funds (PLN34.3/share) and indicates present fair price at PLN36.1/share.


PLN m	2021	2022	2023F	2024F
Investment profits	380	141	107	109
Net profit	465	143	76	77
NAV/share	35.2	36.5	38.0	39.4
P/E (x)	2.2	nd	13.5	13.2
P/NAV (%)	55%	53%	51%	49%

Source: MCI Capital ASI (2021-22), Noble Securities (2023F-2024F)

The preparation of report was finalized on 20/04/2023 at 8:15 a.m.. The first publication took place on 20/04/2023 at 8:20 a.m.



Current price	19.5 zł
Valuation	36.1 zł
Upside/downside	85%
Market cap.	PLN 1023m
Free float	22%
Avg. Vol. 6M	5 491



Source: Bloomberg, Noble Securities

# **COMPANY PROFILE**

MCI Capital is a one of the leading private equity fund in Central-Eastern Europe. Since 1999 group realised over 100 investment projects and finished over 58 exits. Assets under management are estimated over PLN 2B

SHAREHOLDERS	
Tomasz Czechowicz	77.85%
Others	22.15%

# Krzysztof Radojewski

Deputy Head of Research and Advisory Department

krzysztof. radojewski@noble securities.pl

+48 22 213 22 35



# VALUATION

We calculated the value of one share of MCI Capital using Net Asset Value (NAV) method on the basis of book value of investment portfolio at the end of 2023 and peers valuation to the other few European PE companies. We give both methods equal weights (methodology unchanged).

In table below we present valuation summary:

Valuation summary	Weight (x)	Per share (PLN)	Previously (PLN)	change %
Net asset value (NAV)	0.50	38.0	33.1	15%
Peers	0.50	34.3	26.0	32%
Average valuation		36.1	29.6	22%
Current price		19.5	16.1	21%
Upside/downside		85%	84%	

Source: Noble Securities

# PEER VALUATION

We value assets held by MCI Capital at book value, which should reflect fair value. The P/BV valuation ratios of selected European PE companies are shown below. The main difference between these companies and MCI Capital is their higher market capitalization. In our previous October 2022 report, the P/BV ratio for the peers was 0.79x and for MCI was 0.48x, and currently the peers are valued at P/BV of 0.94x and MCI at 0.53x (MCI's valuation discount to the peer group is about 43%). In our opinion, such a high discount to book value in the case of MCI is not justified. Based on the valuation ratios of European private equity companies, we value the company using the comparative method at PLN 34.3 per share (previously PLN 26).

Company	Currency	Market cap (PLN m)	P/BV (x) L12M	Div. yield
3I GROUP PLC	PLN	86 784	1.15	3.0%
GIMV NV	PLN	5 805	0.97	5.6%
EURAZEO	PLN	24 398	0.78	3.3%
DEUTSCHE BETEILIGUNGS AG	PLN	2 478	0.86	5.3%
Mean			0.94	
MCI Capital	PLN	842	0.53	3.6%
Premium/discount to mean (%)			-43%	
Implied fair value of MCI Capital	PLN		34.3	

Source: Bloomberg, Noble Securities, data on 19/04/2023 at 11:21 a.m.



•	·		
2021	2022	2023F	2024F
31	17	15	15
380	141	107	109
41	0	0	0
0	0	0	0
358	137	102	103
-11	-24	-26	-26
346	113	76	77
119	30	0	0
465	143	76	77
	31 380 41 0 358 -11 346 119	31         17           380         141           41         0           0         0           358         137           -11         -24           346         113           119         30	31         17         15           380         141         107           41         0         0           0         0         0           358         137         102           -11         -24         -26           346         113         76           119         30         0

Source: MCI Capital ASI (2021-22), Noble Securities (forecasts, 2023F-2024F)

Balance sheet (PLN m)	2021	2022	2023F	2024F	
Assets	2 064	2 225	2 301	2 378	
Non-current assets	2 014	2 177	2 204	2 198	
Investment certificates	2 009	2 149	2 176	2 170	
Other non-current assets	5	28	28	28	
Current assets	50	48	97	180	
Cash and cash equivalents	21	37	86	169	
Other current assets	29	11	11	11	
Liabilities	2 064	2 225	2 301	2 378	
Equity	1 808	1 916	1 992	2 069	
Non-current liabilities	137	188	188	188	
Liabilities on bonds	110	84	84	84	
Deferred tax liabilities	0	90	90	90	
Others	11	11	11	11	
Current liabilities	16	3	3	3	
Liabilities on bonds	119	121	121	121	
Liabilities on bills of exchange	17	116	116	116	
Other	66	0	0	0	

Source: MCI Capital ASI (2021-22), Noble Securities (forecasts, 2023F-2024F)

Cash flow (PLN m)	2021	2022	2023F	2024F
CF from operating activities	79	15	75	109
CF from investment activities	-2	-5	0	0
CF from financial activities	-95	6	-26	-26
CF	-18	17	49	83
Cash at the beginning of the period	39	21	37	86
Cash at the end of the period	21	37	86	169

Source: MCI Capital ASI (2021-22), Noble Securities (forecasts, 2023F-2024F)

Selected indicators	2021	2022	2023F	2024F
Book value per share	35.2	36.5	38.0	39.4
Dividend per share	0.54	0.70	0.00	0.00
Net debt	172	252	204	120
Net debt/BV	10%	13%	10%	6%
Number of shares issued	51.4	52.5	52.5	52.5
P/BV	0.55	0.53	0.51	0.49

Source: MCI Capital ASI (2021-22), Noble Securities (forecasts, 2023F-2024F)



### LEGAL DISCLAIMER

### FUNDAMENTAL RULES FOR ISSUING ANALYTICAL REPORT

### This analytical report, hereinafter referred to as the "Report", was prepared by Noble Securities S.A. ("NS") based in Warsaw.

The basis for the preparation of the Report were publicly available information known to the Analyst as at the date of preparing the Report, in particular information provided by the Issuer in current and periodic reports prepared as part of its disclosure obligations.

The Report only expresses the analyst's knowledge and views as at the date of its preparation.

The forecasts and evaluation elements presented in the Report are based solely on the analysis performed by the Analyst, without arrangements with the Issuer or with other entities, and are based on a number of assumptions that may turn out to be irrelevant in the future.

 $\ensuremath{\mathsf{NS}}$  or the Analyst do not give any assurance that the forecasts will work.

The report issued by NS is valid for a period of 24 months, unless it is previously updated. The frequency of updates results from the date of publication by the Issuer of financial results for a given reporting period, the market situation or subjective assessment of the Analyst.

### STRONG AND WEAKNESSES OF VALUATION METHODS APPLIED BY NS IN THE REPORT

The DCF (eng. discounted cash flow) method - is considered the methodologically most appropriate valuation technique and consists in discounting financial flows generated by the rated entity. Strengths of this method include taking into account all cash flows that flow in and out of the company and the cost of money over time. The disadvantages of the DCF valuation method are: a large number of assumptions and parameters that need to be estimated and the sensitivity of valuation to changes in these factors. A variation of this method is the discounted dividend method.

Peers valuation - is based on a comparison of valuation multipliers of companies in the industry in which the rated entity operates. This method very well reflects the current state of the market, requires fewer assumptions and is simpler to apply (relatively high availability of indicators for compared entities). Its disadvantages include high volatility related to price fluctuations and stock exchange indices (in the case of comparison to listed companies), subjectivism in the selection of a group of comparable companies and simplification of the company image leading to the omission of some important parameters (eg growth rate, corporate governance, non-operational assets, differences in accounting standards).

### INTERESTS OR CONFLICTS OF INTERESTS THAT MAY AFFECT THE REPORTING OBJECTIVITY OF THE REPORT

### The report was prepared by NS for consideration, on behalf of the Warsaw Stock Exchange S.A.

The Analyst is not a party to any contract concluded with the Issuer and does not receive remuneration from the Issuer. The Analyst's remuneration for preparing the Report due from NS is not directly related to transactions in brokerage services provided by NS or other types of transactions carried out by NS or any other legal entity that is part of the group to which NS belongs or with transaction fees that they receive NS or these people. It can not be ruled out that the remuneration that may be due in future to a NS Analyst by another title may be indirectly dependent on NS financial results, including those obtained as part of investment banking transactions related to the Issuer's financial instruments. The Analyst is not a party to any contract concluded with the Issuer and does not receive remuneration from the Issuer. The Analyst's remuneration for preparing the Report due from NS is not directly related to transactions in brokerage services provided by NS or other types of transactions carried out by NS or any other legal entity that is part of the group to which NS belongs or with transaction fees that they receive NS or these people. It can not be ruled out that the remuneration that may be due in future to a NS Analyst by another title may be indirectly dependent on NS financial results, including those obtained as part of investment banking transactions related to the Issuer's financial instruments.

It is possible that NS has or will have the intention to submit an offer to provide services to the Issuer.

NS is or has been within 12 months a party to agreements with the Issuer concerning provision of brokerage services.

NS has offered financial instruments of the Issuer in the last 12 months.

NS is or has been within 12 months a party to agreements with the Issuer's Parent Company concerning provision of brokerage services.

NS acts as a market maker in relation to financial instruments of the Issuer's Parent Company.

NS within last 12 months offered financial instruments of Parent to Issuer.

# ORGANIZATIONAL AND ADMINISTRATIVE SOLUTIONS AND INFORMATION BARRIERS ESTABLISHED TO PREVENT CONFLICT OF INTERESTS AND TO AVOID THEMSELVES

Detailed rules of conduct in the event of conflicts of interest are set out in the "Regulations of Conflicts of Interest Management at Noble Securities SA" available at the website www.noblesecurities.pl in the tab: "About us" / "Regulations" / "Information policy".

The internal structure of NS ensures organizational separation of analysts from individuals (teams) performing activities that involve the risk of a conflict of interest and prevents conflicts of interest, and in the event of such conflict enables protection of the Client's interests against the harmful effects of this conflict. In particular, Analysts do not have access to information about transactions concluded on the NS's own account and to Client orders. NS ensures that there is no possibility for third parties to exert any adverse influence on the performance of the work by Analysts. NS ensures that there are no links between the amount of remuneration of employees of one organizational unit and the amount of remuneration of employees of another organizational unit, or the amount of income earned by that other organizational unit, if these units perform activities that involve the risk of a conflict of interests

NS has implemented internal regulations regarding the flow of confidential and professional information, which is aimed at securing confidential information or professional secrecy and preventing its unjustified flow or misuse. NS limits to a minimum the circle of people who have access to confidential information or professional secrecy. In order to control access to relevant non-public information, within NS there are internal limitations and barriers in the transfer of information, so-called *Chinese walls*, i.e. rules, procedures and physical solutions to prevent the flow and use of confidential information and constitute professional secrecy. NS uses restrictions in physical access (separate rooms, lockable filling cabinets) and in access to information systems.

NS has implemented regulations in the scope of performing activities consisting in preparing investment analyzes, financial analyzes and other general recommendations regarding transactions in financial instruments, as well as the internal procedure regulating the subject scope. NS discloses in the content of Reports prepared by itself all connections and circumstances that could affect the objectivity of the Reports being prepared. It is forbidden to accept material or non-material benefits by NS or the Analyst from entities having a significant interest in the content of the Report, suggesting to the Issuer by NS or Analyst content favorable to that Issuer. It is forbidden to make available to the Issuer or other persons than Analysts, the Report, containing the content of the recommendation or the target price, before commencing its distribution for purposes other than verification of the NS's compliance with its legal obligations.


NS has implemented internal regulations regarding the rules of concluding personal transactions by involved persons, including prohibits the use of information obtained in connection with business activities for personal transactions. In addition, Analysts may not enter into personal transactions regarding the Issuer's financial instruments or related financial instruments prior to the dissemination of the Report, as well as personal transactions that conflict with the content of the Report and when NS starts or works on issuing Issuer's financial instruments since the Insurer's information in in this respect until the prospectus is published - in the case of a public offer or for launching an offer.

# OTHER INFORMATION AND RESERVATIONS

NS ensures that the Report has been prepared with due diligence and integrity based on generally available facts and information recognized by the Analyst as reliable, reliable and objective, however NS nor the Analyst does not guarantee that they are fully accurate and complete. If the Report indicates the addresses of the websites used in the preparation of the Report, neither the Analyst nor NS takes responsibility for the content of these websites.

Investing can involve high investment risk. The analytical report cannot be treated as an assurance or guarantee of avoiding losses, or achieving potential or expected results, in particular profits or other benefits from transactions carried out on its basis, or in connection with refraining from such transactions. A general description of financial instruments and the risk related to investing in individual financial instruments is presented at www.noblesecurities.pl in the tab Brokerage House / Brokerage Account/ Documents. NS points out that although the above information has been prepared with due diligence, in particular in a reliable manner and in accordance with NS's best knowledge, it may not be exhaustive and may exist or be updated in the specific situation in which an investor is or will be located other risk factors than those indicated in the above information by NS. The investor should bear in mind that investments in individual financial instruments may result in the loss of some or all of the funds invested, and even involve the additional costs.

Investors using the Report may not resign from independent assessment and take into account other circumstances than indicated by the Analyst or by NS.





The Report has been prepared in accordance with legal requirements ensuring independence, in particular from the Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards concerning technical means for the purpose of presenting investment recommendations or other information recommending or suggesting an investment strategy and disclosing particular interests or indications of conflicts of interest. The report is an investment study referred to in art. 36 par. 1 Commission Delegated Regulation (EU) 2017/565 of 25 April 2016 supplementing Directive 2014/65 / EU of the European Parliament and of the Council with regard to organizational requirements and operating conditions for investment firms and concepts defined for the purposes of this directive.

### The Report or any of its entries do not state:

- offer within the meaning of art. 66 of the Act of 23 April 1964 the Civil Code,
- grounds for concluding a contract or creating a liability,
- public offering of financial instruments within the meaning of art. 3 of the Act of July 29, 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies,
- invitations to subscribe for or purchase securities of the Issuer,
- investment advisory services or portfolio management services referred to in the Act of 29 July 2005 on Trading in Financial Instruments,
- investment, legal, accounting or other types of advice.

#### The Report

- is published on the NS website: https://noblesecurities.pl/dom-maklerski/analizy2/program-wsparcia-pokrycia-analitycznego-gpw/1794-mci-capital-s-a,
- is intended for distribution only on the territory of the Republic of Poland, and is not intended for distribution or transmission, directly or indirectly, in the United States of America, Canada, Japan or Australia, or any other jurisdiction, where such distribution would violate relevant provisions of the given jurisdiction or required registration in that jurisdiction,
- does not contain all information about the Issuer and does not allow full assessment of the Issuer, in particular as regards the Issuer's financial situation, because only certain data regarding the Issuer were selected for the Report,
- is for information purposes only, so it is not possible to comprehensively evaluate the Issuer based on the Report.

#### FINAL REMARKS

Analyst preparing the Report: Krzysztof Radojewski

Date and time of completion of the Report: 20/04/2023 at 8.15 a.m.. Date and time of the first dissemination of the Report: 20/04/2023 at 8.20 a.m..

The proprietary copyrights to the Report are held by the Stock Exchange in Warsaw S.A. Dissemination or reproduction of the Report (in whole or in any part) without the written consent of the Warsaw Stock Exchange S.A. is forbidden.

NS is subject to the supervision of the Polish Financial Supervision Authority.

	Recent research concerning MCI Capital S.A.							
Direction	na	na.	na.	na.	na.	na.	na.	
Date	02/05/2022 at. 8:30 a.m.	10/07/2021 at 8:20 a.m.	05/14/2021 at 10:19 a.m.	11/12/2019 at 11:50 a.m.	30/06/2020 at 5:20 p.m.	12/03/2020 at 4:08 p.m.	28.06.2019 at 2:55 p.m.	
Stock price at the date of report	19.0	22.5	19.2	15.0	12.1	8.3	7.3	
Valuation per share	33.1	41.2	30.9	30.4	24.9	21.9	26.5	
WIG Index at the date of report	57 754.98	71 789.34	62 004.52	56 230.40	49 569.17	37 164.02	60187.43	
			Recent research o	concerning MCI Ca	apital S.A.			
Direction							na.	
Date							07.10.2022 at 10:15 a.m	
Stock price at the date of report							16.1	
Valuation per share							29.6	
WIG Index at the date of report							47 299.55	



# All recommendations distributed by NS in last 12 months:

Company	Direction	Target price	Price at publication	Current price	Difference to price target	Date of publication (1)	Validity date (2)	Prepared by (3)
Amica	Accumulate	84,8	79,7	78,30	8%	24.03.2023	9M	Mateusz Chrzanowski
Dino Polska	Reduce	358,6	415,5	397,10	-10%	21.03.2023	9M	Dariusz Dadej
Eurocash	Buy	18,7	13,8	17,79	5%	21.03.2023	9M	Dariusz Dadej
Pepco Group	Accumulate	50,1	43,7	39,68	26%	20.02.2023	9M	Dariusz Dadej
LW Bogdanka	Buy	72,5	52,8	41,30	76%	27.01.2023	9M	Michał Sztabler
Molecure	Buy	20,8	14,7	24,00	-13%	05.01.2023	9M	Krzysztof Radojewski
Celon Pharma	Buy	30,9	15,1	13,84	123%	05.01.2023	9M	Krzysztof Radojewski
Captor Therapeutics	Buy	192,0	164,0	160,00	20%	05.01.2023	9M	Krzysztof Radojewski
Ryvu Therapeutics	Buy	85,4	54,6	58,00	47%	05.01.2023	9M	Krzysztof Radojewski
Forte	Hold	21,3	21,0	26,20	-19%	03.01.2023	9M	Dariusz Dadej
LW Bogdanka	Buy	51,5	38,2	41,30	25%	28.12.2022	9M	Michał Sztabler
Wielton	Hold	6,6	6,7	8,70	-24%	28.12.2022	9M	Michał Sztabler
						12.12.2022		Michał Sztabler
TIM	na	37,9	28,2	49,00	-23%		24M	
Aplisens	na	18,3	14,4	17,40	5%	06.12.2022	24M	Michał Sztabler
Apator	Reduce	12,9	15,0	16,16	-20%	06.12.2022	9M	Michał Sztabler
Sonel	na	10,2	9,7	10,85	-6%	06.12.2022	24M	Michał Sztabler
MO-BRUK	Buy	371,7	293,0	288,00	29%	26.10.2022	24M	Dariusz Dadej
LW Bogdanka	Hold	30,5	30,6	41,30	-26%	20.10.2022	9M	Michał Sztabler
Selvita	Accumulate	97,5	86,0	77,00	27%	20.10.2022	9M	Krzysztof Radojewski
Ailleron	na	17,5	12,0	20,90	-16%	17.10.2022	24M	Dariusz Dadej
MCI Capital	na	29,6	16,1	19,50	52%	07.10.2022	24M	Krzysztof Radojewski
Bioton Dino Polska	na Reduce	4,7	3,8	3,58	31%	06.09.2022 10.08.2022	24M 9M	Krzysztof Radojewski Dariusz Dadej
Eurocash	Accumulate	286,8 13,0	351,5 12,1			10.08.2022	9M	Dariusz Dadej
Amica	Hold	69,7	71,4			05.08.2022	9M	Michał Sztabler
Wielton	Reduce	4,9	5,5			12.07.2022	9M	Michał Sztabler
Krynicki Recykling (4)	na	20,9	22,6			04.07.2022	24M	Dariusz Dadej
Captor Therapeutics	Buy	163,0	116,0			28.06.2022	9M	Krzysztof Radojewski
Celon Pharma	Buy	29,3	14,9			28.06.2022	9M	Krzysztof Radojewski
Molecure	Buy	21,7	13,2			28.06.2022	9M	Krzysztof Radojewski
Ryvu Therapeutics	Buy	51,8	23,5			28.06.2022	9M	Krzysztof Radojewski
CD Projekt  Ten Square Games	Suspended Suspended	na	117,0			24.06.2022 24.06.2022	9M 9M	Maciej Kietliński Maciej Kietliński
Apator	Reduce	na 12,2	14,8			06.06.2022	9M	Michał Sztabler
Aplisens	na	16,0	14,1			06.06.2022	24M	Michał Sztabler
Sonel	na	10,2	9,8			06.06.2022	24M	Michał Sztabler
TIM	na	54,3	31,4			06.06.2022	24M	Michał Sztabler
11 bit studios	Suspended	na	502,0			18.05.2022	9M	Maciej Kietliński
Forte	Accumulate	38,9	33,0			13.05.2022	9M	Dariusz Dadej
MCI Capital	na	33,1	19,0			02.05.2022	24M	Krzysztof Radojewski

<sup>(1)</sup> Date of publication is simultaneously date of first publication,

 $<sup>(2) \</sup> recommendation \ is \ valid \ for \ a \ period \ of \ 9 \ months, \ unless \ it \ is \ previously \ updated,$ 

<sup>(3)</sup> Job position: Krzysztof Radojewski – Deputy Head of Research and Advisory Department, Michał Sztabler – Equity Analyst, Dariusz Dadej - Equity Analyst, Maciej Kietliński ended his work in NS on 06/30/2022

<sup>(4)</sup> Delisted on 9/12/2022.



# MARKET RESEARCH DEPARTMENT

# Sobiesław Kozłowski, MPW

sobieslaw.kozlowski@noblesecurities.pl tel: +48 22 213 22 39 model portfolios

# Krzysztof Radojewski

 $krzysztof.radojewski@noblesecurities.pl\\biotechnology$ 

### Michał Sztabler

michal.sztabler@noblesecurities.pl tel: +48 22 213 22 36 industrials, utillities, mining

### Dariusz Dadej

dariusz.dadej@noblesecurities.pl tel: +48 22 660 24 83 retail, industrials

# Krzysztof Ojczyk, MPW

krzysztof.ojczyk@noblesecurities.pl tel: +48 12 422 31 00 technical analysis

# Mateusz Chrzanowski

 $\underline{mateusz.chrzanowski@noblesecurities.pl}$ 

# Dariusz Nawrot

<u>dariusz.nawrot@noblesecurities.pl</u> tel. +48 783 391 515